SynAct Pharma AB (FRA:8F8)

Market Cap	105.04M +140.1%
Revenue (ttm)	n/a
Net Income	-9.61M
EPS	-0.20
Shares Out	n/a
PE Ratio	n/a
Forward PE	77.11
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	11
Open	2.045
Previous Close	2.030
Day's Range	2.010 - 2.045
52-Week Range	0.881 - 2.320
Beta	n/a
RSI	42.56
Earnings Date	Feb 18, 2026

About SynAct Pharma AB

SynAct Pharma AB, a clinical stage biotechnology company, researches and develops medicines for the treatment of inflammatory diseases in Sweden. The company develops AP1189, a drug candidate in Phase 2 clinical trial for the treatment of rheumatoid arthritis, idiopathic membranous nephropathy, and virus-induced respiratory insufficiency. It is also developing TXP-11, an advanced peptide agonist that is in preclinical trials for the prevention of organ failure in surgery; and various drug programs to treat auto-immune and inflammatory diseases....

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2012
• Employees: 8
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 8F8

Financial Performance

Financial numbers in SEK